Meeting
2014 ASCO Annual Meeting
Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).
Authors
Rashid Khan
MIRT/UAMS, Little Rock, AR
Rashid Khan , Christoph Johann Heuck , Adam Rosenthal , Madhav V. Dhodapkar , Scott E. Miller , Pingping Qu , Donald Joseph Johann Jr., Frits Van Rhee , Yogesh Jethava , Maurizio Zangari , Shmuel Yaccoby , Phillip Farmer , Monica Grazziutti , Joshua Epstein , Antje Hoering , John Crowley , Bart Barlogie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8604)
DOI
10.1200/jco.2014.32.15_suppl.8604
Abstract #
8604
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.
First Author: Wilson I. Gonsalves
Poster
2024 ASCO Annual Meeting
From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
First Author: Mengmeng Ji
Poster
2023 ASCO Annual Meeting
Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma.
First Author: Shaji Kumar
Poster
2022 ASCO Annual Meeting
African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.
First Author: Theresia Akhlaghi